ABBV - AbbVie

-

$undefined

N/A

(N/A)

AbbVie NYSE:ABBV AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Location: 1 North Waukegan Road, North Chicago, IL, 60064-6400, United States | Website: https://www.abbvie.com | Industry: Drug Manufacturers - General | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

389.9B

Cash

5.176B

Avg Qtr Burn

N/A

Short % of Float

1.12%

Insider Ownership

0.10%

Institutional Own.

74.50%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
RINVOQ (upadacitinib) Details
Giant Cell Arteritis (GCA)

Approved

Quarterly sales

EMRELIS™ (telisotuzumab vedotin-tllv) Details
NSCLC With High c-Met Protein Overexpression

Approved

Quarterly sales

TrenibotulinumtoxinE (TrenibotE) Details
Moderate to Severe Glabellar Lines

BLA

Acceptance for review

Tavapadon (adjunct with L-Dopa) Details
Parkinson's disease, Brain disease

Phase 3

Update

Tavapadon Details
Parkinson's disease, Brain disease

Phase 3

Update

Phase 2

Update

Emraclidine (CVL-231) Details
Brain disease, Schizophrenia

Phase 2

Update

Phase 2

Update

NX-13 Details
Ulcerative colitis

Phase 2

Update

Darigabat Details
Social Anxiety Disorder, Panic Disorder

Phase 2

Update

CVL-354 Details
Major depressive disorder

Phase 1

Update

Emraclidine (CVL-231) Details
Brain disease, Neurodegenerative disease, Alzheimer's disease

Phase 1

Update